Street taps Epocrates for research

Share this article:

The research arm of investment banking firm Goldman Sachs will look to promote Epocrates' marketing research services. Financial terms of the three-year agreement were not disclosed.

Hudson Street, a Goldman Sachs business, will seek to connect Epocrates to buyside investors and portfolio managers for use in investigating potential pharma and biotech investments.

“We have a highly targeted panel that they can reach,” said Kirk Loevner, Epocrates chairman and chief executive officer.

Epocrates claims 500,000 active clinician users in its subscriber base. Of those, 200,000 are active US physicians, and 145,000 of those have opted into the marketing research service.

Epocrates, also known for its clinical information and decision support tools, already works with about 150 marketing research firms. They are drawn to the vendor's ability to tap into its physician panel, by specialty and by geography, and get answers to surveys. 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"